Hayes B A, Balster R L
Eur J Pharmacol. 1985 Oct 29;117(1):121-5. doi: 10.1016/0014-2999(85)90480-7.
Primarily on the basis of activity in [3H]phencyclidine (PCP) binding assays and drug discrimination studies, a number of structurally dissimilar compounds have been found to be PCP-like. Drugs from four of these classes of PCP-like compounds were examined for anticonvulsant activity in the pentylenetetrazol (PTZ) seizure test. Male albino mice, eight per dose, were administered the drug or vehicle i.p. 10 min before PTZ (125 mg/kg s.c.). At each dose, the number of subjects and latency to clonic and/or tonic seizures within 15 min following PTZ were recorded. The anticonvulsant properties of PCP, ketamine, (+)-N-allylnormetazocine, etoxadrol, dexoxadrol and (-)-2-methyl-3,3-diphenyl-3-propanolamine ((-)-2-MDP) were selective for tonic seizures. The highest dose tested for each compound completely prevented the occurrence of tonic seizures. Levoxadrol and (+)-2-MDP, drugs devoid of PCP-like activity in other tests, were also inactive in the PTZ seizure test. These results demonstrate that similarities among PCP-like drugs previously shown using binding assays and drug discrimination procedures can be extended to include anticonvulsant effects, and they suggest common cellular sites of action for these properties.
主要基于[3H]苯环己哌啶(PCP)结合试验和药物辨别研究中的活性,已发现许多结构不同的化合物具有PCP样特性。对这些类PCP样化合物中的四类药物进行了戊四氮(PTZ)惊厥试验中的抗惊厥活性研究。每剂量8只雄性白化小鼠,在PTZ(125mg/kg皮下注射)前10分钟腹腔注射药物或赋形剂。在每一剂量下,记录给药后15分钟内出现阵挛性和/或强直性惊厥的动物数量和潜伏期。PCP、氯胺酮、(+)-N-烯丙基去甲左啡诺、依托沙朵、右旋依托沙朵和(-)-2-甲基-3,3-二苯基-3-丙醇胺((-)-2-MDP)的抗惊厥特性对强直性惊厥具有选择性。对每种化合物测试的最高剂量完全预防了强直性惊厥的发生。左啡诺和(+)-2-MDP在其他试验中没有PCP样活性,在PTZ惊厥试验中也无活性。这些结果表明,先前在结合试验和药物辨别程序中显示的PCP样药物之间的相似性可以扩展到包括抗惊厥作用,并且提示这些特性具有共同的细胞作用位点。